Least Developed Countries Sample Clauses
Least Developed Countries. Notwithstanding paragraphs 1 and 4 of Article 139, Least Developed Countries party to this Agreement shall be required to apply the following provisions only as established herein:
Least Developed Countries. Africa (34): Angola, Benin, Burkina Faso, Burundi, Central African Republic, ▇▇▇▇, Comoros, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Niger, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Togo, Uganda, United Republic of Tanzania, Zambia Asia (14): Afghanistan, Bangladesh, Bhutan, Cambodia, Kiribati, Lao People’s Democratic Republic, Myanmar, Nepal, Samoa, Solomon Islands, Timor-Leste, Tuvalu, Vanuatu, Yemen Latin America and the Caribbean (1): Haiti (Source: United Nations Office of the High Representative (UN-OHRLLS) as of October 23, 2013) [***] NIH Patent License Agreement Nonexclusive - Sublicensable
I. The Licensee agrees to pay to the NIAID a noncreditable, nonrefundable license issue royalty in the amount of [***] within sixty (60) days from the effective date of this Agreement.
Least Developed Countries. Notwithstanding Article 139(1) and (4), Least-Developed Countries party to this Agreement shall be required to apply the following provisions only as established herein: (a) the obligations under the TRIPS Agreement on equal pace with what may be required of them with regard to the implementation of the TRIPS Agreement under the relevant decisions of the Council for TRIPS or other applicable decisions by the WTO General Council; (b) the obligations under Subsections 2 and 3 of this Section, not later than 1 January 2021, unless the CARIFORUM-EC Trade and Development Committee determines otherwise taking into account the relevant decisions mentioned in subparagraph (a).
Least Developed Countries. EARNED ROYALTY shall not be due and payable to JHU on NET REVENUES generated from: (i) LICENSED PRODUCTS sold in Least Developed Countries as defined by the United Nations Country Classification in the most recent United Nations’ publication “Statistical Annex” (“LEAST DEVELOPED COUNTRIES”); or (ii) LICENSED PRODUCTS sold to the Public Sector providing LICENSED PRODUCTS at a Cost-Based Price in such Least Developed Countries, but only if COMPANY sells such LICENSED PRODUCTS at COMPANY’s cost of production thereof.
Least Developed Countries. Afghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Cape Verde, Central African Republic, Chad, Comoros, Congo Dem. Rep., Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kiribati, Laos, Lesotho, Liberia, Madagascar, Malawi, Maldives, Mali, Mauritania, Mozambique, Myanmar, Nepal, Niger, Rwanda, Sao Tome and Principe, Sierra Leone, Solomon Islands, Somalia, Sudan, Tanzania, Togo, Tuvalu, Uganda, Vanuatu, Western Samoa, Yemen, Zambia.
Least Developed Countries. BiondVax shall comply, and shall ensure that its Affiliates and Sublicensees comply, with the concept of “equitable licenses”, in order to ensure that patients in the “least developed countries” (which countries are classified in the respective list of the United Nations, Department of Economic and Social Affairs, as amended from time to time) get access to Products at affordable costs, as follows: BiondVax shall in its reasonable discretion and after a commercially reasonable time after Regulatory Approval for a BLA for Products, and any other required pricing and/or reimbursement approvals, (i) work in good faith to grant licenses to commercially reasonable Sublicensees at fair, reasonable and non-discriminatory terms for the manufacture and sale of Products to patients in at least one or more of the least developed countries at affordable costs, (ii) sell Products subject to the required Regulatory Approvals in the concerned country at affordable costs to patients in the least developed countries, or (iii) declare a non-assert regarding the use of Licensed Patent Rights for the manufacture and sale of Products in the least developed countries at affordable costs.
